Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2009, vol. 18, nr 3, May-June, p. 215–220

Publication type: original article

Language: English

Single−Nucleotide Polymorphism Association Study of VDR and CDH1 Genes and the Risk of Prostate Cancer

Wpływ polimorfizmu typu SNP w genach VDR i CDH1 na ryzyko rozwoju raka prostaty

Patrik Forszt1,, Agnieszka Pilecka2,3,, Małgorzata Małodobra2,4,, Joanna Markowska3,, Krzysztof Maksymowicz3,, Tadeusz Dobosz2,

1 Regional Specialist Hospital, Research and Development Center, Wroclaw, Poland

2 Department of Forensic Medicine, Molecular Technique Unit, Wroclaw Medical University, Wroclaw, Poland

3 Department and Unit of Forensic Medicine, Wroclaw Medical University, Wroclaw, Poland

4 Warsaw University of Medicine, Postgraduate School of Molecular Medicine, Warsaw, Poland

Abstract

Background. Prostate cancer (PC) is considered the most common cause of male cancer mortality. A positive family history is one of the strongest risk factors for prostate cancer. Numerous data indicate that PC has a genetic background; however, it cannot be explained as a single−gene disease but as a multigenetic disorder.
Objectives. The aim of this study was to search for genetic correlation between single−nucleotide polymorphisms (SNPs) in the VDR and CDH1 genes and the risk of PC.
Material and Methods. One hundred PC patients and 100 control subjects were investigated. The SNPs rs2107301 and rs2238135 in VDR and rs16260 in CDH1 were detected by minisequencing followed by capillary electrophoresis. Hardy−Weinberg equilibrium, the chi−squared test, and non−parametric tests (Wald−Wolfowitz and Mann−Whitney U) were used for statistical analyses.
Results. Two of the three tested SNPs, i.e. rs2238135 in VDR and rs16260 in CDH1, displayed statistically significant differences in frequency between the two groups (p = 0.0266 and p = 0.0123 for rs2238135 and rs16260, respectively). The C/C genotype of rs2107301 in VDR gene positively correlated with increased prostrate−specific antigen (PSA) level (p = 0.0073).
Conclusion. The results provide unique data and show strong association between the tested SNPs in the VDR and CDH1 genes and malignancy and progression of prostate cancer.

Streszczenie

Wprowadzenie. Rak prostaty (r.p.) jest obecnie jedną z najczęstszych przyczyn śmierci z powodu nowotworów wśród mężczyzn. Jednym z czynników ryzyka jest wywiad rodzinny w kierunku raka prostaty. Wiele danych przemawia za tym, iż r.p. ma podłoże genetyczne o wielogenowym charakterze dziedziczenia.
Cel pracy. Poszukiwanie korelacji między polimorfizmem typu SNP w genach VDR i CDH1 a ryzykiem rozwoju raka prostaty.
Materiał i metody. Zbadano 100 pacjentów z rakiem prostaty oraz 100 zdrowych mężczyzn w podobnym przedziale wiekowym. Analizie poddano rs2107301 oraz rs2238135 znajdujące się w genie VDR oraz rs16260 w genie CDH1. Uzyskane wyniki poddano analizie statystycznej z zastosowaniem testu χ2 oraz testów nieparametrycznych (Wald−Wolfowitza i U Mann−Whitneya).
Wyniki. Dwa z trzech analizowanych polimorfizmów: rs2238135 w genie VDR oraz rs16260 w genie CDH1 wykazało istotne statystycznie różnice w częstości występowania między badanymi grupami (p = 0,0266 i p = 0,0123 dla rs2238135 i rs16260, odpowiednio). Poza tym genotyp C/C rs2107301 dodatnio korelował z podwyższonym poziomem PSA u chorych (p = 0,0073).
Wnioski. Wprzestawionej pracy wykazano korelację między polimorfizmami w genach VDR i CDH1 a rozwojem raka prostaty wśród pacjentów z regionu Dolnego Śląska.

Key words

prostate cancer, SNP, VDR gene, CDH1 gene

Słowa kluczowe

rak prostaty, polimorfizm typu SNP, VDR, CDH1

References (19)

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer Statistic 2008. CA Cancer J Clin, 2008, 58, 71–96.
  2. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of prostate cancer. Prostate 1990, 17, 337–347.
  3. Forrest MS, Edwards MS, Houlston R, Kote−Jarai Z, Key T, Allen N, Knowles MA, Turner F, Ardern−Jones A, Murkin A, Williams S, Oram R, Bishop DT, Eeles RA: Association between hormonal genetic polymorphisms and early−onset prostate cancer. Prostate Cancer Prostatic Dis 2005, 8, 95–102.
  4. Schaid DJ: The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004, 13(1), 103–121.
  5. Gos M, Sadowska M, Wiechno P, Demkow T, Janik P: Tło genetyczne a ryzyko rozwoju raka prostaty oraz obraz kliniczny choroby. Urol Pol 2006, 59, Supl. 1.
  6. Thorne J, Campbell MJ: The vitamin D receptor in cancer. Proc Mutr Soc 2008, 67(2), 115–127.
  7. Holick CN, Stanfork JL, Kwon EM, Ostrander EA, Nejentsev S, Ulrike P: Comprehensive association analysis of the Vitamin D pathway genes, VDR, CYP27B1, and CYP24A1 in Prostate Cancer. Cancer Epidemiol Biomarkers Pre 2007, 16(10), 1990–1999.
  8. Moon S, Holle S, Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange R: Associations between G/A1229, A/G30875, C/T48200 and C/T65013 genotypes and haplotypes in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer. Ann Hum Gen 2006, 70, 226–236.
  9. Mikhak B, Humter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E: Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interaction with plasma 25−hydroxvitamin D and 1,25−dihydroxyvitamin D and prostate cancer risk. Prostate 2007, 67(9), 911–923.
  10. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM. Hunter D, Giovannucci EL, Ma J: A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms and prostate cancer. Plos Med 2007, 3, e103.
  11. Ingles SA, Ross RK, Yu MC, Irvine RA, LaPera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in Vitamin D Receptor and Androgen Receptor. J Nati Cancer Inst 1997, 89(2), 166–170.
  12. Grunwald GB: The structural and functional analysis of cadherin calcium−dependent cell adhesion molecules. Curr Opin Cell Biol 1993, 5, 797–805.
  13. Dunsmuer WD, Gillett SE, Meyer SC, Young NP, Corbishley C, Eeles RA Kirby RS: Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000, 86, 869–878.
  14. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR: Functional analysis of human promoter polymorphisms. Hum Mol Genet 2003, 12, 2249–2254.
  15. Onen IH, Ekmekci A, Eroglu M, Konac E, Yesil S, Biri H: Association of genetic polymorphisms in vitamin d receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med 2008, 233, 1608–1614.
  16. Bonilla C, Mason T, Long L, Ahaghotu C, Chen W, Zhao A, Coulibaly A, Bennett F, Aiken W, Tullock T, Coard K, Freeman V, Kittles RA: E−cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate 2006, 66(5), 545–556.
  17. Jonsson BA, Adami HO, Hähhlund M, Bergh A, Göransson I, Statin P, Wiklund F, Grönberg H: − 160C/A polymorphism in the E−cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004, 109(3), 348–352.
  18. Lindström S, Wiklund F, Jonsson BA, Adami HO, Bälter K, Brookes AJ, Xu J, Zheng SL, Isaacs WB, Adolfsson J, Grönberg H: Comprehensive genetic evaluation of common E−cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet 2005, 118, 339–347.
  19. Qiu LX, Li RT, Zhang JB, Zhong WZ, Bai JL, Liu BR, Zheng MH, Qian, XP: The E−cadherin (CDH1) −160 C/A polymorphism and prostate cancer risk: a meta−analysis. Eur J Hum Genet 2008 [EPub ahead of print].
© Wroclaw Medical University